EGFR and non-small cell lung carcinoma: A retrospective study indicated that 27% of patients received chemotherapy combined with ICI after the failure of osimertinib (27), suggesting that the efficacy of salvage chemotherapy alone was unsatisfactory, and thus physicians were enthusiastic to explore ICI in EGFR-mutant NSCLC.